Yeah, that’s a great question. We don’t know the answer to that question, so we have several things that we’re doing. One is that probably the CSF and microenvironment itself is kind of toxic to immunotherapies. So we’ve also done work in the lab with Una Smalley, where we did a metabolomic screen of the CSF. And the CSF has this weird metabolism...
Yeah, that’s a great question. We don’t know the answer to that question, so we have several things that we’re doing. One is that probably the CSF and microenvironment itself is kind of toxic to immunotherapies. So we’ve also done work in the lab with Una Smalley, where we did a metabolomic screen of the CSF. And the CSF has this weird metabolism. It makes a lot of branched-chain ketoacids, but these appear to be toxic to T cells and toxic to neurons. So part of the problems that patients are having are because of the toxic metabolism. So we have a way of inhibiting that. And then we’re going to find a way to optimize the dendritic cells. And we’re not quite sure how to do that yet because we’re just looking now at the data of what they’re like in terms of the molecular details of what we’re actually administering. So we’re kind of learning every week about how to do this better. But we completely are working on everything to make it better and to select the right patients who are going to benefit.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
